Veeva Systems Inc. (NYSE: VEEV) is trading at $244.34 as of November 24, 2025, following the announcement of an expanded partnership with Roche Pharmaceuticals.
Veeva Systems Inc., VEEV
Roche will adopt Veeva Vault CRM across its global operations, integrating artificial intelligence capabilities to enhance commercial execution and streamline customer engagement. The update highlights Veeva’s growing influence in life sciences software and AI-driven solutions.
Veeva and Roche have maintained a long-standing relationship, and this expansion represents a major step in their collaboration. Vault CRM is part of Veeva’s CRM Suite of applications, designed to optimize field team operations in the pharmaceutical sector. Veeva CEO Peter Gassner emphasized the significance of deploying the next generation of AI-enabled CRM tools to support Roche’s global pharmaceutical teams.
Roche’s chief digital and technology officer, Wafaa Mamilli, stated that the rollout aims to create personalized interactions with healthcare professionals while equipping teams with actionable insights. This approach intends to improve patient engagement and optimize commercial performance across Roche’s global network.
The Vault CRM platform incorporates Veeva AI, offering agentic AI functionalities through Veeva AI Agents. These include Free Text Agent, Voice Agent, Pre-call Agent, and Media Agent. The integration will enable field teams to access predictive insights, improve engagement efficiency, and personalize communication.
Availability is planned for December 2025, positioning Veeva and Roche at the forefront of AI-powered pharmaceutical CRM.
Veeva Systems provides cloud software, data, and business consulting services to the life sciences industry, serving over 1,500 clients, from major biopharmaceutical companies to emerging biotech firms. VEEV’s performance year-to-date shows a 16.05% return, surpassing the S&P 500’s 13.83%, while the stock has traded at $244.34 at the time of the announcement.
Over three years, VEEV has faced challenges with a 29.74% return compared to the S&P 500’s 66.25%, and a five-year return of -8.13%, reflecting industry-specific pressures.
The expanded partnership with Roche strengthens Veeva’s position in the global CRM market and highlights its ability to leverage AI to enhance commercial operations. The rollout of AI agents within Vault CRM demonstrates Veeva’s commitment to technological innovation, providing Roche with actionable insights to optimize pharmaceutical field interactions.
Veeva Systems’ collaboration with Roche underscores its strategy to expand AI-driven solutions in life sciences. The integration of Vault CRM and Veeva AI is expected to improve commercial execution and engagement effectiveness, supporting VEEV’s continued growth and competitive positioning in the healthcare technology market.
Veeva’s continued innovation and its structured approach as a Public Benefit Corporation strengthen its long-term positioning within the life sciences ecosystem. The company’s push into AI-powered solutions reflects a broader industry transition toward automated decision-making, real-time data access, and tailored engagement models.
As demand for integrated cloud platforms rises across global pharma organizations, Veeva’s expanding suite of applications places it in a strong position to capture future growth opportunities while deepening relationships with top-tier clients such as Roche.
The post Veeva Systems Inc. ( VEEV) Stock: Expands AI-Driven CRM Partnership with Roche appeared first on CoinCentral.

